What are the options for hepatocellular carcinoma patients who progress under sorafenib?
Hepat Oncol
.
2016 Apr;3(2):105-108.
doi: 10.2217/hep-2016-0003.
Epub 2016 Mar 23.
Authors
Eunice Y-T Lau
1
,
Terence K-W Lee
1
Affiliation
1
Department of Applied Biology & Chemical Technology, The Hong Kong Polytechnic University, Hong Kong.
PMID:
30191031
PMCID:
PMC6095157
DOI:
10.2217/hep-2016-0003
No abstract available
Keywords:
HCC; PD-1; biomarker; resistance; sorafenib.
Publication types
Editorial